Unadjusted and adjusted analyses comparing the impact of TNF antagonist monotherapy with thiopurine monotherapy and combination therapy on risk of severe COVID-19
| Medication comparison | OR (95% CI) | aOR (95% CI) | P value* | P value† | Total n in model | N with severe COVID-19 |
| TNF antagonist (ref=No TNF antagonist)‡ | 0.47 (0.29 to 0.62) | 0.69 (0.43 to 1.10) | 0.12 | 0.52 | 1415 | 111 |
| Combination therapy | 3.29 (1.31 to 8.25) | 4.01 (1.65 to 9.78) | 0.002 | 0.008 | 670 | 34 |
| Thiopurine monotherapy (ref=TNF antagonist monotherapy)§ | 3.15 (1.55 to 6.43) | 4.08 (1.73 to 9.61) | 0.001 | 0.013 |
*P value for adjusted model.
†Adjusted p value using Bonferroni correction method for six hypothesis tests that were conducted.
‡Model adjusted for age, sex, race (black vs non-Hispanic white, Asian vs non-Hispanic white), Hispanic versus non-Hispanic, disease type, disease activity, cardiovascular disease, corticosteroids, thiopurine, diabetes, lung disease and cancer.
§Model adjusted for age, sex, race (Asian vs non-Asian), disease type, disease activity, cardiovascular disease, corticosteroids and sulfasalazine/mesalamine.
aOR, adjusted OR; TNF, tumour necrosis factor.